Clinical trial
CJD (Creutzfeldt-Jakob Disease) Quinacrine Study
NCT00183092 · University of California, San Francisco, Other · Completed
Key facts
| NCT number | NCT00183092 |
|---|---|
| Title | CJD (Creutzfeldt-Jakob Disease) Quinacrine Study |
| Official title | Novel Therapeutics For Prion Diseases: A Randomized, Double-blinded, Placebo-controlled Study of the Efficacy of Quinacrine in the Treatment of Sporadic Creutzfeldt-Jakob Disease |
| Lead sponsor | University of California, San Francisco, Other |
| Collaborators | National Institute on Aging (NIA) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Creutzfeldt-Jakob Disease |
| Intervention type | Drug |
| Interventions | Quinacrine, Placebo |
| Enrollment | 69 |
| Start date | Apr 1, 2005 |
| Primary completion | Jun 1, 2012 |
| Completion | Jun 1, 2012 |
| First posted | Sep 16, 2005 |
| Last update posted | Jun 9, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: